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Objective: In rheumatoid arthritis (RA) patients, low levels of physical activity (PA) and
high levels of sedentary behavior (SB) may play a role in enhancing cardiovascular risk.
We do not know how long-term control of disease activity impacts upon daily PA levels
and if treated patients attain PA levels seen in healthy controls. We therefore compared
habitual levels of PA and SB between female RA patients with low disease activity
achieved by anti-tumor necrosis factor (TNF) therapy, those with active arthritis (aRA)
and non-RA controls.
Methods: We carried out a cross-sectional comparison of 40 RA patients on anti-TNF therapy for
>2 years with DAS28<3.2 (tRA), 32 patients on conventional disease modifying anti-rheumatic
drugs with DAS28>3.2 (aRA) and 34 healthy controls (C) with the groups matched for age and
body mass index. PAwas assessed using the ActiGraph accelerometer to determine step count and
time spent in moderate-to-vigorous physical activity (MVPA), light activity and sedentary time.
Results: Daily step count was 72% higher in tRA and 40% higher in C in comparison to
aRA (p<0.01). Sedentary time (as a proportion of wear time) was 10% less in tRA than aRA
(p=0.03), while light activity time was 18% higher (p=0.014). Both RA groups had 40%
lower MVPA time than C (p=0.001). Only half of either RA group fulfilled current WHO
guidelines for PA compared with 82% of controls.
Conclusion: RA patients who had long-term disease suppression were more physically active
with less SB compared to RA patients with active disease. They had similar light PA and SB to
controls although lower MVPA. Behavioral change interventions are likely to be needed in order
to restore moderate exercise, further reduce SB and to meet guidelines for daily PA.
Keywords: rheumatoid arthritis, physical activity, sedentary behavior, accelerometry
Introduction
In the general population, there is good evidence that sedentary behavior (SB;
defined as time spent sitting) is hazardous to health.1–4 SB has been associated
with an increased risk of type 2 diabetes, cardiovascular disease, cancer and all-
cause mortality, often independently of body mass index (BMI) and physical
activity (PA).1–4 Recent evidence has suggested that high levels of moderate-to-
vigorous physical activity (MVPA), for example, at least 60–90 mins per day, may
have a protective effect against the health consequences associated with high levels
of sitting.5 However, these high levels of activity may not be achievable by the
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majority of the population given the current low levels of
MVPA engagement.6 Experimental evidence has sug-
gested that breaking up long periods of sitting with light
and moderate intensity activity improves glucose and insu-
lin levels and blood pressure in those at risk of chronic
disease.7–9 Avoiding a sedentary lifestyle (characterized by
prolonged periods of sitting) is likely to reduce the afore-
mentioned health risks, and delay the onset of age-related
functional limitation by reducing muscle and bone loss and
preventing falls and fractures.10
Rheumatoid arthritis (RA) is characterized by joint
swelling, muscle wasting, fatigue and elevated cardiovas-
cular risk associated with cytokine-driven systemic
inflammation.11 Several controlled studies using
accelerometry12–14 have shown reduced total PA in
patients with RA compared to healthy controls although
others have shown no difference.15–17 Nevertheless, the
balance between SB, light PA and MVPA is likely to be
most important and indeed Prioreschi et al12 have reported
that RA patients spend around 2 hrs more each day in
sedentary activities than healthy controls. Such SB may
persist due to inadequate control of inflammation, habit or
psychological factors and lead to serious long-term con-
sequences for the health of the individual. Basic research
has suggested that SB induces a pro-inflammatory and
potentially atherogenic state by cellular mechanisms
including reduction in lipoprotein lipase activity leading
to a rise in triglycerides and cholesterol.18 This may help
to perpetuate RA and add to its comorbidities.19 RA
patients who are physically active have better psychologi-
cal wellbeing than those who are inactive,12 exhibit fewer
cardiovascular risk factors,16,20–23 fewer hospital
admissions,24 have higher bone mineral density (BMD)
and reduced bone loss.25
Anti-tumor necrosis factor (TNF) therapy has revolu-
tionized the management of RA with rapid and sustained
improvements in pain, function, quality of life26 and work-
force participation.27 Improving locomotor, cardiovascular
and psychological health is likely to depend upon not only
control of inflammation but also restoring PA. We do not
know however how long-term control of disease activity
impacts upon habitual daily PA and SB levels and whether
treated patients attain PA levels seen in healthy controls.
The aim of this study was to assess habitual levels of PA
and SB in women with RAwho had experienced long-term
low disease activity achieved by anti-TNF therapy com-
pared to RA patients with active arthritis (aRA) and non-
RA controls.
Patients and methods
Study protocol
This cross-sectional study measured PA and SB levels in
three groups of patients: RA patients on their first anti-TNF
drug for >2 years with consistently low disease activity
(tRA), RA patients with moderate to high disease activity
on conventional disease modifying anti-rheumatic drug
(cDMARD) therapy who had never had a biologic drug
(aRA) and non-RA controls (C). Anti-TNF patients were
selected as the participants of this study as these individuals
had documented high RA disease activity in the past and
had regular subsequent measurements recorded confirming
low disease activity. A 2-year minimum time period on anti-
TNF was considered appropriate based on the clinical
observation that at least one year was required for an
individual to adjust physically and mentally to a low disease
activity state. The aRA group was chosen as a comparator
as these patients would have been similar in terms of RA
disease activity and treatment to the tRA group before they
were established on biologic therapy. High disease activity
patients were selected for the aRA group where possible,
particularly those undergoing assessment with a view to
biologic therapy. The study was limited to women in
order to maintain consistency. The sample size for this
study was based on information quoted in the paper by
Roubenoff et al.14 In order to detect an effect size in activity
energy expenditure as reported by these authors of 1,264
±992 kJ/day in patients versus 2,280±1,469 kJ/day in con-
trols with a power of 90% at 95% significance level would
require 32 participants per group. Forty patients per group
were planned to allow for dropouts and inadequate data
recording (20%) yielding a target sample size of 120 parti-
cipants in total. At the time of planning our study, there
were no other relevant accelerometry papers.
Participants
Women 18 years or above, resident in the catchment areas of
the Royal Derby Hospital and local community hospitals
were eligible for the study. Potential participants were iden-
tified from the Departmental anti-TNF database and from the
health records of patients attending the clinic. Exclusion
criteria were pregnancy or breastfeeding within the previous
12 months, oral corticosteroid therapy, insulin-dependent
diabetes, structural damage to a lower limb joint or joint
replacement, use of a walking aid or any significant disorder
which might influence the result of the trial or the person’s
ability to participate in the trial. tRA patients were recruited if
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their 3 monthly DAS28 scores were consistently ≤3.2 for 2
years or more and at study entry. aRA had a DAS score >3.2
on entry to the study. Controls were recruited by advertise-
ment among hospital staff and through the local newspaper.
They were volunteers who considered themselves to be
healthy and had no restrictions on PA. Exclusion criteria
similar to other participants were applied. No remuneration
other than for parking charges was provided. Anti-TNF
patients were recruited first of all and participants in the
other two groups were selected so as to match the group
means for age and BMI.
Assessments
RA clinical assessment
Rheumatoid disease activity was measured using the DAS28
score with tender and swollen joint counts (TJC, SJC), patient
global health VAS and erythrocyte sedimentation rate. Low
Rheumatoid disease activity was defined as DAS28≤3.2 and
moderate to high disease activity as DAS28>3.2.28 The Health
Assessment Questionnaire (HAQ) was used as a standard
measure of functional disability.
Anthropometry
Height, body mass and waist circumference were recorded,
and a GE Lunar Prodigy dual-energy X-ray absorptiometry
scanner was used to measure fat mass and BMD.
Questionnaires
The SF-36 v2 questionnaires were completed at the end of
the 7-day monitoring period. Participants were questioned
regarding alcohol consumption, current and previous
smoking.
Accelerometry
Participants wore an ActiGraph GT3X + accelerometer
(ActiGraph, Pensacola, FL, USA) throughout waking hours
(taken off at bedtime) for seven consecutive days, except
during water-based activities, on an elasticated belt on the
waist above the mid-line of the right thigh. The device was
initialized at a frequency of 30 Hz and downloaded using
ActiLife software version 6.9.0. The low-frequency exten-
sion filter was selected during the download process, and data
were downloaded into 60-s epochs. Accelerometer data were
considered valid if there were >600 mins of monitoring per
day (excluding continuous strings of zero counts for 60 mins
or longer) recorded on at least three weekdays and one week-
end day.29 The widely used <100 counts/min (cpm) cut-point
was employed to estimate sedentary time (ie, estimated time
spent sitting)30 while the Freedson cut-points (applied to the
vertical axis) were used to estimate time spent in light inten-
sity activity (100–1,951 cpm) (such as slow walking) and
MVPA (such as brisk walking or jogging/running) (≥1,952
cpm).31 Information on daily step counts was also retrieved
from the device. Mean times spent per day in SB, light
intensity activity and MVPA, along with the proportion of
time spent per day in each behavior (accounting for accel-
erometer wear time) were calculated for each participant over
the 7-day monitoring period.
Statistical analysis
Analysis was performed using SPSS for Windows version 23
(IBM Corporation, Armonk, NY, USA) Data were checked
and distributions assessed using Kolmogorov–Smirnov tests
and visual inspection of histograms and Q–Q plots. Means and
SDs (or median and inter-quartile ranges) were calculated. For
normally distributed data, comparisons between groups were
conducted using ANOVA with Bonferroni post hoc tests.
Variables that were not normally distributed were compared
between groups using independent samples Kruskal–Wallis
test or Mann–WhitneyU-test as appropriate. Categorical vari-
ables were compared using chi-squared tests. One-way
ANOVAs compared mean daily step counts across the three
study groups. The proportions of daily accelerometer wear
time spent sedentary, in light activity and in MVPA were
compared between groups to control for differences in accel-
erometer wear time. Body composition variables (fat mass and
waist circumference) as well as BMDat the spine and hip were
analyzed using one-way ANOVAs to test for differences
between the three groups. The ANOVAs were repeated using
% fat as a covariate in view of the reported association of BMI
and fat mass with PA, particularly MVPA.32 Statistical sig-
nificance was set at p<0.05 for all analyses.
Results
Participants
The three groups were similar in age, ethnicity, height, body
mass, BMI and BMD although fat mass and waist circumfer-
ence were greater in aRA than C (Table 1). Prevalence of
current smoking or alcohol consumption did not differ
between groups although a lower proportion of controls had
a history of smoking. Among RA patients, measurements of
functional disability (HAQ) and rheumatoid disease activity
(DAS28, TJC, SJC andVAS)were significantly higher in aRA
than tRA as expected by the selection criteria (Table 1). RA
disease duration was significantly greater in tRA than aRA;
34% aRA patients were taking more than one cDMARD. In
Dovepress Summers et al
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Table 1 Characteristics of tRA, aRA and control (C) groups
Variable tRA (n=40) aRA (n=32) C (n=34) p
Age (years) 59.0±10.4 60.4±10.6 60.8±10.5 0.748
Height (cm) 163.2±7.1 163.7±6.9 162.1±6.0 0.606
Body mass (kg) 68.6±13.1 74.4±16.7 66.3±10.4 0.054
BMI (kg m−2) 25.7±4.5 27.7±5.6 25.1±3.2 0.072
Waist circumference (cm) 86.3±12.5 91.5±10.5c 83.6±8.9c 0.019
% Fat 38.0±7.3 40.9±6.9c 37.7±6.3c 0.041
Left femoral neck BMD (T-score) −0.8±1.1 −1.0±1.0 −0.6±0.9 0.317
L2–4 BMD (T-score) −0.1±1.7 −0.2±0.3 −0.4±1.4 0.725
Ethnicity§
White British 35 (88%) 31 (97%) 31 (91%) 0.210
Asian Chinese 0 (0%) 0 (0%) 1 (3%)
Asian Indian 1 (3%) 0 (0%) 2 (6%)
Black Caribbean 0 (0%) 1 (3%) 0 (0%)
Mixed 2 (5%) 0 (0%) 0 (0%)
Other 2 (5%) 0 (0%) 0 (0%)
History of smoking§ 19 (48%) 19 (59%) 9 (26%) 0.024
Current smoking§ 2 (5%) 2 (6%) 1 (3%) 0.813
Alcohol consumption§
≥4 times/week 6 (15%) 4 (13%) 8 (24%) 0.691
2–3 times/week 6 (15%) 7 (22%) 9 (26%)
2–4 times/month 15 (38%) 8 (25%) 7 (17%)
Monthly or less 8 (20%) 6 (19%) 4 (12%)
Never 5 (13%) 7 (22%) 6 (18%)
Duration of RA (years) 15.8±9.2a 9.6±9.6a – 0.006
TJC* 1 (0-2)a 13 (9-22)a – <0.001
SJC* 0 (0-2)a 8 (7-12)a – <0.001
ESR* 11 (6-22) 13 (7-24) – 0.202
VAS* 12 (10-20)a 50 (20-78)a – <0.001
DAS28 2.7 (0.9)a 5.3 (1.2)a – <0.001
HAQ summary score 0.7±0.6a 1.2±0.6a c 0.1±0.1c <0.001
Treatment
Anti-TNF
Etanercept 37 (93%) –
Adalimumab 2 (5%) –
Infliximab 1(2%) –
cDMARD
Methotrexate 21 (53%) 20 (63%)
Sulfasalazine 4 (10%) 6 (19%)
Hydroxychloroquine 1 (3%) 16 (50%)
Leflunomide – 6 (19%)
D-Penicillamine – 2 (6%)
Notes: Figures are presented as mean ± SD unless otherwise indicated; *Median (inter-quartile range), or §Number (%). According to Bonferroni post hoc tests: atRA
significantly different from aRA, btRA significantly different from the control group, caRA significantly different from the control group. The p-values shown in bold are
statistically significant, p<0.05.
Abbreviations: aRA, rheumatoid arthritis patients with active arthritis; BMD, bone mineral density; BMI, body mass index; cDMARD, conventional disease modifying
anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender
joint count; TNF, tumour necrosis factor; tRA, rheumatoid arthritis patients on anti-TNF therapy.
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tRA, 37 patients were taking Etanercept, two Adalimumab
and one Infliximab and 60% were also taking a cDMARD.
Accelerometery
All but two participants provided ActiGraph data, col-
lected over a mean of 6.6 days. Total daily wear time
for the whole sample was 854±71 mins/day. ActiGraph
wear time differed marginally between the three groups
(Table 2); therefore, the proportions of time spent in
each behavior (sedentary, light activity and MVPA)
were used in the primary analyses. Significant differ-
ences were observed between groups in the proportions
of time spent sedentary, in light activity, and MVPA
(Table 2). Post-hoc comparisons revealed that tRA
spent a 10% lower proportion of time sedentary
(p=0.03) and an 18% higher proportion of time in light
intensity PA (p=0.014) in comparison to aRA. No sig-
nificant differences were observed between the controls
and either aRA or tRA in the proportions of time spent
sedentary and in light activity. Both tRA and aRA had
40% lower MVPA time in comparison to controls (both
p=0.002). No significant differences in the proportion of
time spent in MVPA were observed between the two RA
groups. Mean daily step counts differed significantly
between groups (Table 2), with tRA accumulating 72%
more daily steps and Controls 40% more steps in com-
parison to aRA (p<0.001). No significant differences in
daily steps were observed between tRA and controls.
Findings were not affected when results for three
patients in the tRA group taking a biologic other than
Etanercept were excluded. Adjustment of the results for
the difference in % fat between the groups resulted in
no material change in the level of significance (Table 3).
Patient-reported outcome
The SF-36 physical health score differed significantly
between the groups with C>tRA>aRA.
Discussion
Our study has documented that patients on long-term anti-
TNF therapy have higher levels of overall PA (as estimated
by steps/day) when compared to those with aRA as well as
similar levels to healthy controls. This is mirrored by the
HAQ scores which reflect mainly low intensity daily PAs and
personal care showing that a stable period of prolonged low
RA disease activity allows the rheumatoid patient to achieve
a degree of normality with regards their overall PA behavior.
Table 2 Physical activity and questionnaire data for tRA, aRA and control (C) groups
ActiGraph data tRA(n=40) aRA (n=31) C (n=33) p
Step count (steps/day) 12808 ± 6005a 7452 ± 3788ac 10446 ± 4120c <0.001
Wear time (min/d) 862 ± 64 831 ± 78 870 ± 69 0.065
% sedentary 56.3 ± 10.8a 62.6 ± 10.9a 58.4 ± 7.2 0.030#
% light 40.8 ± 9.6a 34.5 ± 1.0a 36.8 ± 6.9 0.014
% MVPA 2.9 ± 2.2b 2.9 ± 2.2c 4.8 ± 2.8bc 0.002
WHO exercise guidelines fulfilled (%) 50.0% 48.4% 81.8% 0.007**
SF36 mental health (0–100)* 50.6 ± 9.5a 44.7 ± 12.2ac 54.0 ± 5.5c 0.001
SF36 physical (0–100)* 44.0 + 9.0ab 35.9 + 11.1ac 55.4 + 5.5bc <0.001
Notes: Figures are presented as mean ±SD unless indicated otherwise. SF-36: *The lower the score the worse the health. According to Bonferroni post hoc tests: atRA
significantly different from aRA, btRA significantly different from the control group, caRA significantly different from the control group. **p value from Chi-squared test. #p
value for aRA v C = 0.09.
Abbreviations: aRA, rheumatoid arthritis patients with active arthritis; MVPA, moderate to vigorous physical activity; tRA, rheumatoid arthritis patients on anti-TNF therapy.
Table 3 Physical activity data adjusted for % body fat
Adjusted ActiGraph data tRA
(n=38)
aRA
(n=30)
Control group (n=33) p
% sedentary 55.6 (1.6)a 62.1 (1.8)a 58.6 (1.7) 0.030
% light 41.4 (1.4)a 34.9 (1.6)a 36.7 (1.6) 0.009
% MVPA 3.0 (0.4)b 3.0 (0.4)c 4.7 (0.4) b,c 0.006
Notes: Data are presented as mean (standard error). According to Bonferroni post hoc tests: atRA significantly different from aRa. btRA significantly different from the
control group, caRA significantly different from the control group. The p-values shown in bold are statistically significant, p<0.05.
Abbreviations: aRA, rheumatoid arthritis patients with active arthritis; MVPA, moderate to vigorous physical activity; tRA, rheumatoid arthritis patients on anti-TNF therapy.
Dovepress Summers et al
Open Access Rheumatology: Research and Reviews 2019:11 submit your manuscript | www.dovepress.com
DovePress
137
 
O
pe
n 
Ac
ce
ss
 R
he
um
at
ol
og
y:
 R
es
ea
rc
h 
an
d 
Re
vie
ws
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
23
1.
15
5.
38
 o
n 
16
-J
ul
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Step count is an important indicator of general health: in RA
patients, for example, step count is highly correlated to aero-
bic capacity, a standard assessment of cardiorespiratory
fitness.33 Similarly, in the general population evidence
demonstrates a linear association between step counts and a
range of morbidity and mortality outcomes, as well as with
markers of health status including inflammation, adiposity,
insulin sensitivity and high-density lipoprotein-cholesterol in
adults.34–36 Regardless of an individual’s baseline value,
even modest increases in daily step counts should, therefore,
yield clinically meaningful health benefits for RA patients.
A further finding of our study is that low disease activity
patients (tRA) were less sedentary than the aRA group with
similar SB to the controls. In comparison to the aRA group
lower % sedentary time was also associated with a higher %
time in light activity. This suggests that long-term suppres-
sion of RA disease activity may result in the “rebalancing”
of SB and light-intensity activity. These results are in accord
with the one previous study looking at SB in relation to RA
disease activity: Prioreschi et al37 studied 18 drug-naive RA
patients at baseline and after 3 months of DMARD therapy
finding that improvements in RA disease activity were
associated with a fall in sedentary time and an increase in
time spent in light PA. The findings may have major impli-
cations for the cardiovascular health of RA patients: a study
by Fenton et al38 comparing cardiovascular risk factors with
PA revealed significant positive associations between seden-
tary time and 10-year CVD risk, with the reverse true for
light PA participation. Associations were independent of
MVPA engagement. Khoja et al21 also found that the asso-
ciations between accelerometer-measured PA and cardio-
vascular disease markers in RA patients were either
equivalent or stronger at very light and light intensities, as
compared to moderate intensity.
An unexpected finding from the current study was the lack
of difference in % sedentary time between those with aRA
and controls. The expectation was that SB would be higher in
the aRA group although the results do not support this: aRA
patients were sedentary for a mean of 63% of the wear time in
comparison to 58% for controls (p=0.09). It could be that a
difference that was too small to detect with the sample size in
this study. Nevertheless, similar results have been reported in
other cross-sectional studies comparing SB in RA to healthy
controls15,39 although Prioreschi et al12 found a higher seden-
tary time in RA. The lack of difference between the RA group
and controls in one study was thought to be due to a “ceiling
effect” with a high level of SB of 91% accelerometer wear
time in both groups.15 The interpretation of SB is therefore
complex as there may be different causes. In RA, pain, stiff-
ness and fatigue are likely to be important whereas healthy
controls may paradoxically have a higher sitting time through
greater work participation. A recent study of office workers
drawn from the same geographical area to the present study
found that they were sedentary for 68% of wear time on work
days and 60% non-work days.40 The issue of employment
was not explored in the current study. It is clear however that
there are high levels of SB among RA patients as well as in
the general population. RA patients are already susceptible to
obesity, muscle wasting, osteoporosis, cardiovascular disease,
depression and fatigue as a result of chronic systemic inflam-
mation, perhaps partly mediated through increased SB.
Reduction in SB is arguably even more urgent in this section
of the population requiring both pharmacological and non-
pharmacological approaches to management. Thomsen et
al,41 for example, have recently shown that a 16-week indi-
vidually tailored, theory-based behavioral intervention with
motivational counseling and SMS reminders reduced daily
sitting time by an average of 2 hrs as well as total cholesterol
in sedentary patients with RA.
MVPA may be difficult for some people with RA to
achieve and maintain. Our study demonstrated that RA
patients with good disease control on long-term anti-TNF
therapy continue to exhibit a deficit in MVPA compared to
healthy controls with a level of MVPA similar to patients
with active RA. Nevertheless, even for controls, MVPA
accounted for only 5% of accelerometer wear time. These
results are supported by the data from the SF-36 physical
component score in which most questions are concerned
with MVPA rather than light activity. Previous accelero-
metry studies also show a reduction in MVPA in RA
patients compared to healthy individuals13,16 although
Huffman et al15 in their extremely sedentary population
found no difference to controls. Guidelines for PA42
recommend at least 150 mins moderate PA or 75 mins of
vigorous activity per week in adults. Of our population,
82% of the controls, 48% aRA and 50% tRA fulfilled the
criteria. It is well documented that exercise interventions
are effective in promoting cardiovascular health in
RA.43,44 There is a need for PA and exercise programmes
that support RA patients in overcoming barriers in order to
sustain this important health behavior.45
Our study has a number of strengths and limitations.
Comparing RA patients experiencing long-term disease sup-
pression (tRA) with healthy controls and patients with aRA
has allowed us to highlight the achievements and deficiencies
of our current management in relation to restoring an
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individual’s PA. Nevertheless, as this is a cross-sectional
study the conclusions should ideally be supported by pro-
spective data. We are therefore unable to attribute the
observed differences between the RA groups directly to the
beneficial effects of sustained low rheumatoid disease activ-
ity. Indeed, we are also unable to say for certain whether the
observed effects were due to low disease activity or anti-TNF
per se. Nevertheless, improvement in patient-reported PA
outcomes similar to those achieved by anti-TNF are also
seen following disease suppression with other drugs,46 sug-
gesting that the observed effects on PA in this study are due to
disease suppression rather than being drug specific. Our
choice of cDMARD patients as a comparison group was a
pragmatic one as such patients are common. The alternative
choice of “anti-TNF failure” patients might have allowed us
to distinguish between the effects of low disease activity and
anti-TNF but there are far fewer such patients in our clinic
and they are rapidly escalated to alternative biologic therapy.
Additionally such a group is not free from possible channel-
ing bias: for example, “anti-TNF failure” patients have a
higher rate of smoking and obesity.47 Our choice of a 2-
year minimum time frame for the anti-TNF therapy has
been subsequently supported by the results of follow-up
studies showing maximum improvement in DAS28 and
HAQ at about one year with no significant change up to 5
years.48 Because of the inclusion and exclusion criteria, the
results may not be generalizable to the whole RA population.
The study was limited to women for the sake of consistency
so some of the conclusions may not apply to men. There is
some evidence, for example, that men in the general popula-
tion engage in more MVPA than women.49 It was not possi-
ble to BMI match the tRA with the aRA groups closely
because of the higher BMI of patients meeting the aRA
criteria attending our clinics although controlling for fat
mass did not substantially change the results (Table 3). The
shorter disease duration in aRA in comparison to tRA reflects
the increasing tendency over the past few years to manage
patients more aggressively and escalate to biologic treatment
early in the disease course. The relatively small sample size
limited our ability to detect differences between groups. The
three groups contained a wide age spectrum (between 30 and
77 years) which might be viewed as a limitation of the study.
Population studies show that levels of total and light PA are
stable during midlife (ages 31–59) but decline subsequently
whereas MVPA levels fall gradually from about age 50
years.50 Nevertheless, the groups were closely matched for
mean age and age distribution (Table 1), allowing for valid
comparison. Additionally, the patients we recruited were all
in good health, apart from RA, potentially minimizing the
age drop-off in PA seen in unselected populations. While the
ActiGraph accelerometer has been widely used as an objec-
tive measure of SB, this waist-worn device is not capable of
distinguishing between standing and sitting/lying postures.
Therefore, some periods of standing still may have been
misclassified as SB. Further research exploring SB in RA
patients should use inclinometers to strengthen the measure-
ment of sedentary time.30
Conclusion
We have demonstrated that RA patients with low rheuma-
toid disease activity due to long-term anti-TNF therapy are
more physically active and have lower SB compared with
RA patients with active disease. Anti-TNF treated patients
are similar to healthy controls in terms of total PA, SB,
disability and fat mass although have a persisting deficit in
MVPA. Although new biologic therapies have been suc-
cessful in restoring RA patients to a more normal exis-
tence, we need to design behavioral change interventions
in order to optimize our management of patients with RA.
Moderate exercise should be encouraged where possible,
but it also appears that reducing SB and encouraging light
PA is an effective strategy in promoting cardiovascular and
musculoskeletal health in RA.
Ethics approval and informed
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Approval was granted by the Southern Derbyshire Ethics
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Anti-TNF drugs, Biopharmaceuticals given by regular injec-
tion which block the action of TNF; aRA, RA patients on
conventional DMARDs with high disease activity
(DAS>3.2); BMD, Bone mineral density; BMI, Body mass
index; C, non-rheumatoid arthritis healthy controls;
cDMARD, conventional disease modifying anti-rheumatic
drug; DAS28/DAS score, a measure of the severity of rheu-
matoid arthritis using clinical and laboratory data, specifi-
cally the numbers of tender and swollen joints from a set of
28, the patient’s global health score (0-10) and the erythro-
cyte sedimentation rate or CRP; HAQ, Health Assessment
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Questionnaire; MVPA, moderate-to-vigorous physical activ-
ity; PA, physical activity; Q–Q plot, Quantile-quantile prob-
ability plot; RA, Rheumatoid arthritis; SB, sedentary
behavior; SF-36, 36 item Short Form questionnaire to mea-
sure physical and mental health; SJC, Swollen joint count;
SPSS, Statistical Package for the Social Sciences; TJC,
Tender joint count; TNF, Tumour necrosis factor alpha
which is produced in excess in RA causing inflammation,
pain and damage to the bones and joints; tRA, Rheumatoid
arthritis patients on anti-TNF therapy with low disease activ-
ity (DAS<3.2); VAS, 10 cm visual analogue scale.
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